Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Vol.18, 2026.6.2
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: In 2026, the Qiming Weekly gets a refresh. Updated regularly every week, it features just ten handpicked highlights from Qiming Venture Partners' portfolio companies — covering funding milestones and breakthrough developments.
Every step entrepreneurs take amid the waves of technology and innovation deserves to be recorded. Qiming Venture Partners will continue accelerating and empowering founders, and we invite you to join us in marking these milestone moments for our portfolio companies.
Major Partnership
Insilico Medicine Partners with Human Longevity
Recently, Qiming Venture Partners portfolio company Insilico Medicine (03696.HK) announced a multi-million dollar strategic partnership with Human Life Foundation Models ("HLFM"), a newly established company under Human Longevity. The collaboration aims to jointly develop the industry's first large-scale AI foundation model for human longevity science research.
Under this partnership, Insilico Medicine and HLFM will co-develop superintelligent AI foundation models to decode the biological mechanisms of aging and enable predictive diagnosis and treatment. Within this framework, Insilico Medicine will leverage its expertise in multimodal foundation model development and deep learning system architecture, drawing on MMAI Gym's advanced model training and evaluation framework to systematically deliver model architecture design, benchmarking, training guidelines, and core computational algorithms — providing the technical foundation for the jointly developed models.
Product Launches
01/
StepFun Releases Step 3.7 Flash
Recently, Qiming Venture Partners portfolio company StepFun officially released and open-sourced Step 3.7 Flash. This is the next-generation Flash model from StepFun, designed for the agent production era. Rather than simply pursuing "faster" or "cheaper" lightweight models, it systematically optimizes for agent workflows, coding, search, and multimodal pipelines — striving for a better balance between speed, cost, reliable execution, and complex task completion. Multimodal, fast, practical, and hassle-free.
As agents begin entering enterprise workflows, development pipelines, knowledge work, and automation systems, models need to satisfy multiple requirements simultaneously: fast enough, stable enough, cheap enough, reliable enough, and easy enough for developers to integrate and deploy. This is the core direction of Step 3.7 Flash: not just single-point speed, but real task completion efficiency; not just single-turn Q&A, but multi-turn, tool-enabled, context-rich, multimodal agent workflows. Going forward, StepFun will continue releasing more technical blogs, scenario demos, developer case studies, and ecosystem partnership programs around Step 3.7 Flash — exploring agent efficiency evaluation methods, engineering practices, and production pathways together with developers.
02/
Xiaoe Tech GEO Growth Engine Officially Launches
Recently, Qiming Venture Partners portfolio company Xiaoe Tech officially launched its GEO Growth Engine. Built specifically for merchants, this public-domain growth solution spans content production to performance validation, with three modules connecting the complete chain.
Content Hub Module: Through keyword configuration and brand asset uploads, merchants can build dedicated content libraries. The system generates professional content on relevant themes by combining brand materials, providing merchants with professional content output support.
Media Resource Module: Integrates multiple types of publishable media channels, categorized by media attributes and industry sectors, while displaying relevant channel case studies. Merchants can quickly match suitable content distribution channels to precisely reach target audiences.
Performance Testing Module: Provides brand citation testing functionality that simulates real user query scenarios on mainstream platforms, detecting brand keyword mentions and related description directions. Merchants can use this to validate content placement effectiveness, identify public-domain operation weaknesses, and clarify optimization directions — forming a closed-loop management system from content production to performance validation.
R&D Progress
01/
Cornerstone Robotics' Sentire Laparoscopic Surgical Robot Receives Dual EU CE and Singapore HSA Certifications
Recently, Qiming Venture Partners portfolio company and Chinese innovative surgical robotics firm Cornerstone Robotics announced that its self-developed Sentire laparoscopic surgical robot has officially passed EU CE certification (MDR) and simultaneously obtained Singapore HSA certification. Both certifications cover endoscopic surgery in urology, general surgery, gynecology, and thoracic surgery. This dual milestone breakthrough means Sentire is now formally approved to enter core medical markets in Europe and Asia-Pacific. Sentire had previously completed clinical trials in the United Kingdom, further validating its clinical application capabilities and accelerating the global adoption of high-quality surgical robots.
Professor Guowei Ou, Founder and CEO of Cornerstone Robotics, stated: "Obtaining EU CE and Singapore HSA certifications represents a crucial milestone for Cornerstone Robotics as we advance from deep technology development to global clinical application. From completing our first clinical validation in Portsmouth, UK, to now formally passing stringent multi-regulatory approvals, every step reflects our team's persistent pursuit of independent core technology innovation and clinical value. We firmly believe that in the highly competitive international market, the key to winning long-term trust lies in exceptional product quality and solid clinical performance. Going forward, we will continue deepening our presence in core global medical markets, relying on professional local teams and one-stop service systems to partner with world-leading medical institutions in bringing high-quality surgical robot solutions to more patients and healthcare providers worldwide."
02/
HugeMed Opens First MEA Training Center in Turkey
Qiming Venture Partners portfolio company HugeMed, in collaboration with renowned expert Prof. Kemal Sarica, has officially established its first Middle East and Africa Training Center at SBÜ Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital in Turkey. From product introduction to clinical exchange, from single-device applications to systematic training around RIRS technology, HugeMed has continuously participated in and witnessed the growth of minimally invasive urological diagnosis and treatment capabilities in Turkey.
Going forward, the training center will use Turkey as a pivot point, providing systematic growth pathways for more physicians across the Middle East and Africa region through ongoing academic courses, surgical observation, hands-on training, and international exchanges — while also providing solid support for the standardized application and promotion of RIRS technology.
03/
Gan & Lee Pharmaceuticals Receives ANVISA GMP Certification Again
Recently, Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) announced that it has successfully passed Good Manufacturing Practice (GMP) certification from Brazil's National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária, ANVISA). This certification covers two core formulation products: insulin aspart and insulin lispro, with the certificate holder being its subsidiary Gan & Lee Pharmaceuticals Brazil Trading and Pharmaceutical Import Ltd.
In April this year, Gan & Lee Pharmaceuticals' insulin aspart and insulin lispro had just passed ANVISA's active pharmaceutical ingredient (API) GMP certification. This means the company has achieved dual compliance certification for both APIs and formulations in Brazil for its insulin glargine, insulin lispro, and insulin aspart products. Its production quality systems now fully comply with local pharmaceutical regulatory standards, laying a solid foundation for the company's own insulin brands to formally enter the Brazilian market and deepen its presence in the Latin American pharmaceutical blue ocean.
04/
YourHealth Medical Opens Lu's Acupuncture Specialty Clinic
Recently, Qiming Venture Partners portfolio company YourHealth Medical grandly opened its "Lu's Acupuncture Specialty Clinic" in Shanghai. The clinic brings together multiple direct inheritors of the Lu's Acupuncture school, preserving the core essence of this national intangible cultural heritage. It aims to systematically provide conditioning programs featuring Lu's Acupuncture for chronic disease and sub-health populations, promoting the application of this heritage acupuncture practice in high-quality medical settings, while exploring innovative pathways for multidisciplinary collaboration.
Dr. Haoying Shi, Founder and CEO of YourHealth Medical and President of Shanghai YourHealth Hospital, stated: "YourHealth Medical's opening of the 'Lu's Acupuncture Specialty Clinic' aims to inherit the century-old essence of Lu's Acupuncture's syndrome-differentiation and treatment methodology, integrating it with modern medical diagnostic standards to create complementary advantages between traditional Chinese medical wisdom and modern healthcare systems — providing higher quality and more professional TCM diagnosis and treatment services for patients at home and abroad. YourHealth consistently adheres to personalized service concepts, deeply practicing the core TCM principle of 'preventive treatment of disease,' running prevention-first and holistic conditioning throughout the entire diagnosis and treatment process, providing each patient with full-cycle health management from health assessment, precise treatment to continuous follow-up — truly achieving people-centered, mind-body harmonious health guardianship."
05/
OriCell Therapeutics' Ori-C101 Shows Promising Data in Late-Line Advanced Liver Cancer
Qiming Venture Partners portfolio company and global innovative tumor immunotherapy leader OriCell Therapeutics recently announced that its self-developed GPC3-targeting CAR-T cell therapy product Ori-C101 demonstrated excellent anti-tumor activity and controllable safety in the registrational Phase Ib (BEACON) trial for patients with advanced late-line hepatocellular carcinoma (HCC) who failed second-line therapy. Related data was selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
As of April 3, 2026, Ori-C101 showed breakthrough efficacy in the registrational Phase I clinical trial (BEACON study): among 18 evaluable subjects, overall anti-tumor activity was significant with an ORR of 50%. Particularly in the Phase II recommended dose (RP2D) cohort, efficacy was further pronounced with an ORR of 66.7% and disease control rate (DCR) approaching 90%, significantly outperforming existing second-line standard therapies.
Dr. Huanfeng Yang, Founder and CEO of OriCell Therapeutics, stated: "Following our first selection in 2021, this marks the third time our CAR-T product clinical data has earned an ASCO oral presentation. This not only powerfully validates OriCell Therapeutics' 'trinity' technology platform's clinical translation capabilities, but also fills us with confidence for the future. We will accelerate this product's development, striving to complete the pivotal Phase II clinical study and enter commercialization as soon as possible to benefit patients globally. We welcome collaborations based on our platform technology, product development, and commercialization aspects, so that more cancer patients can benefit."
Technical Strength
01/
Hesai Technology's Fermi C500 Becomes First RISC-V LiDAR Master Control Chip to Pass ISO 26262 Functional Safety Certification
Recently, Qiming Venture Partners portfolio company, global intelligent technology enterprise, and 3D perception technology leader Hesai Technology (NASDAQ: HSAI, 02525.HK) announced that its self-developed Fermi C500 chip has officially passed ISO 26262 ASIL B functional safety product certification from SGS, the internationally recognized testing, inspection and certification organization — becoming the world's first RISC-V LiDAR master control chip to receive this certification. This marks that Hesai Technology's self-developed chips have fully satisfied international mainstream safety standards for automotive-grade LiDAR in functional safety architecture design and random hardware failure risk prevention and control.
ISO 26262 is the world's most authoritative automotive functional safety standard and an important threshold for electronic component suppliers to enter the automotive industry. Covering the full product lifecycle — from functional safety management, conceptual design, system and software/hardware development to production support processes — the standard aims to ensure that automotive electronic and electrical systems comply with stringent international safety specifications throughout design, development, and manufacturing, minimizing potential risks and protecting occupant safety.
02/
Yunji Technology Named Huiyou's "Chief Partner for Full-Scenario Digital Intelligence"
Recently, at the 2026 Huiyou Ecosystem Partners Conference and Group Milestone Ceremony, Qiming Venture Partners portfolio company Yunji Technology (02670.HK) showcased its full-scenario intelligent agents and was honored as "Chief Partner for Full-Scenario Digital Intelligence." Relying on its "Human-Machine Symbiotic World Value Model," Yunji Technology delivered practical results in cost reduction and quality improvement, efficiency empowerment, and diversified revenue growth — initiating a profound transformation in full-scenario digital intelligence operations for hotels.
As Huiyou Hotel Group's contracted and opened properties surpassed 300, Yunji Technology's intelligent agent services have already penetrated multiple properties' normalized operations in consultation, item delivery, and instant retail scenarios. This award not only represents high recognition of Yunji Technology's technological innovation and application capabilities, but also signals that both parties' full-scenario digital intelligence solutions are accelerating implementation, jointly driving the hotel industry toward a smarter, more valuable new cycle.
Previous Issues
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol. 17, 2026.5.26
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since inception, the firm has focused on investing in early and growth-stage outstanding enterprises in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns in their industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 0800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Insilico Medicine (03696.HK), Hope Medicine, Yuanxin Technology, MediLink Therapeutics, LaNova Medicines, StepFun, and others.